Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis  by Welsh, Paul et al.
lable at ScienceDirect
Atherosclerosis 254 (2016) 167e171Contents lists avaiAtherosclerosis
journal homepage: www.elsevier .com/locate/atherosclerosisEffect of IL-6 receptor blockade on high-sensitivity troponin T and
NT-proBNP in rheumatoid arthritis
Paul Welsh a, *, Katie Tuckwell b, Iain B. McInnes c, Naveed Sattar a
a Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
b Roche Products Ltd, Welwyn Garden City, UK
c Institute of Infection, Immunity and Inﬂammation, University of Glasgow, UKa r t i c l e i n f o
Article history:
Received 10 August 2016
Received in revised form
4 October 2016
Accepted 7 October 2016
Available online 8 October 2016
Keywords:
IL-6
Tocilizumab
Troponin
Natriuretic peptide
Rheumatoid arthritis* Corresponding author. BHF Glasgow Cardiovas
University Place, Glasgow, G12 8TA, UK.
E-mail address: Paul.Welsh@Glasgow.ac.uk (P. We
http://dx.doi.org/10.1016/j.atherosclerosis.2016.10.016
0021-9150/© 2016 The Authors. Published by Elseviea b s t r a c t
Background and aims: Observational associations between inﬂammation and cardiovascular disease are
interesting, but randomised experimental data are lacking. We investigated the effect of the IL-6 receptor
blocker tocilizumab on N terminal pro B type natriuretic peptide (NT-proBNP) and high sensitivity
troponin T (hsTnT) in rheumatoid arthritis (RA) patients.
Methods: A post-hoc study was performed in a subset of patients with moderate to severe RA partici-
pating in a randomised controlled trial. The effect of tocilizumab on cardiac biomarkers was determined
using stored serum (baseline and 24 weeks) in recipients of tocilizumab (8 mg/kg every 4 weeks plus
DMARDs; n ¼ 225) or placebo (every 4 weeks plus DMARDs; n ¼ 132).
Results: Median NT-proBNP and hsTnT concentrations at baseline were 100 pg/ml and 5.7 pg/ml,
respectively. NT-proBNP decreased in both study arms (median at 24 weeks 77 pg/ml in the placebo arm,
79 pg/ml in the tocilizumab arm; p<0.001 for the decrease in both arms), and decreased to a similar
extent comparing study arms (tocilizumab effect: 5.5%, p¼0.55). hsTnT also decreased in both study
arms (median at 24 weeks 3.1 pg/ml in the placebo arm, 4.4 pg/ml in the tocilizumab arm; p<0.001 for
the decrease in both arms). The extent of the reduction in hsTnT was greater in the placebo group
(tocilizumab effect: þ23.3%, p¼0.002). Change in NT-proBNP, but not hsTnT, correlated modestly with
change in CRP (r ¼ 0.17, p¼0.013).
Conclusions: These data argue against a rapid preferential beneﬁt of IL-6 blockade on these speciﬁc
surrogate markers of cardiovascular risk, but may be consistent with a general cardiovascular beneﬁt of
improved RA treatment.
Clinical trials.gov identiﬁer: NCT00106574.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Both N terminal pro B type natriuretic peptide (NT-proBNP) and
high sensitivity troponin T (hsTnT) are emerging strong biomarkers
of future cardiovascular disease (CVD) risk in generally healthy
people [1]. People suffering from rheumatoid arthritis (RA) have
elevated circulating concentrations of natriuretic peptides and
troponins, even after adjusting for awide range of classical CVD risk
factors [2e4]. The mechanisms by which cardiac biomarkers are
elevated in RA patients are unclear [2e5], but one potential
pathway may be that systemic inﬂammation drives vascularcular Research Centre, 126
lsh).
r Ireland Ltd. This is an open accesdysfunction and atherosclerosis or indirectly causes cardiac stretch.
The inﬂammatory hypothesis of CVD has evolved from obser-
vations that elevated circulating levels of CRP, or indeed almost any
other circulating inﬂammatory marker, are associated with an
increased risk of future CVD events in general population studies,
even after adjusting for established classical CVD risk factors [6e9].
Mendelian randomisation studies on IL-6 receptor genes support a
causal role for circulating IL-6 in increasing CVD risk [10,11]. Under
the inﬂammatory hypothesis of CVD, speciﬁc interventions to
reduce inﬂammationmay reduce vascular pathophysiology and the
associated hard CVD events. Observational data suggests that
reducing the inﬂammatory burden in people with RA improves
cardiovascular risk [12,13], but thus far randomised data are lack-
ing; randomised controlled trials of anti-inﬂammatory therapies in
autoimmune inﬂammatory conditions have not been designed tos article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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published observational data, pharmaco-epidemiological studies
suggest speciﬁcally that RA patients receiving tumour necrosis
factor alpha (TNFa) blockers are at lower risk of CVD [15]. Data from
an adalimumab treated cohort study reported lowering of NT-
proBNP with treatment, but the study lacked a control arm [16].
Therefore further experiments to test the hypothesis that biologic
therapies improve cardiac biomarker proﬁles in a randomised
setting are warranted.
The present study assessed the short-term effect of tociluzimab
(relative to placebo) on NT-proBNP and hsTnT, perhaps the stron-
gest circulating biomarkers of CVD risk, in the Tocilizumab in
cOmbination With traditional DMARD therapy (TOWARD) phase III
double-blind randomized controlled trial.
2. Patients and methods
2.1. Trial design and participants
TOWARD multinational recruitment was conducted between
March 2005 and August 2006, as previously described [17]. The
study investigated the efﬁcacy and safety of tocilizumab versus
placebo in combination with standard therapy in patients with
moderate-to-severe RA in whom clinical response to classical
disease-modifying antirheumatic drugs (DMARDs) was inadequate.
Patients aged at least 18 years with moderate-to severe RA of at
least 6 months' duration, with a swollen joint count of 6, a tender
joint count of 8, and a C-reactive protein (CRP) level 1 mg/dl or
an erythrocyte sedimentation rate (ESR) 28 mm/h were enrolled.
Treatment with conventional synthetic DMARD therapy was stable
for 8 weeks prior to study entry [17]. Exclusion criteria included
unsuccessful treatment with a TNFa blocker and any cell-depleting
therapy. Tuberculosis screening was managed according to local
practice.
A total of 1220 patients were randomized (2:1 ratio) to receive
either tocilizumab 8 mg/kg intravenously every 4 weeks or placebo
intravenously every 4 weeks for 24 weeks. Patients in both groups
remained on stable doses of DMARDs. The study protocol was
approved by relevant institutional review boards or ethics com-
mittees, and written informed consent was obtained from each
patient.
2.2. Serum sample analysis
Sufﬁcient paired baseline and week 24 samples were available
for 357 patients (225 tocilizumab, 132 placebo) who consented to
donate serum bio-repository samples. Samples were assayed for
hsTnT and NT-proBNP blinded to treatment allocation and time
status. NT-proBNP and hsTnT weremeasured in a single thaw on an
automated clinically validated immunoassay analyser (e411, Roche
Diagnostics, Burgess Hill, UK) using the manufacturer's calibrators
and quality control reagents. High and low control coefﬁcient of
variation for each assay was 6.6%.
2.3. Statistical analysis
Missing biomarker patterns were investigated by comparing
baseline demographics and clinical characteristics.
The distributions of each continuous characteristic were
examined by randomised group at baseline and 24weeks and these
were summarised as means (standard deviation [SD]) when nor-
mally distributed and median (interquartile range [IQR]) when
skewed. Categorical variables were reported as frequencies (per-
centages). Spearman correlations of baseline and change in NT-
proBNP and hsTnT with other biomarkers were tested.The effect of tocilizumab on NT-proBNP and hsTNTwas explored
by linear regression, with log-transformation of skewed bio-
markers. The effect was estimated by comparing the mean 24 week
biomarker concentration in the tocilizumab group with the corre-
sponding mean in the placebo group; this approach adjusted for
baseline. The results are presented as ratios of geometric means
(with corresponding 95% CIs) by exponentiation of the parameter
estimates. The linearity and constant variance assumptions were
checked by examining plots of residuals against ﬁtted values. To
observe a 25% difference in hsTnT between randomised groups at 6
months, with an a of 5% and a power of 80%, we needed 237 par-
ticipants in the tocilizumab group and 119 in the placebo group. To
observe a 10% difference in NT-proBNP between randomised
groups at 6 months, with an a of 5% and a power of 80%, we needed
143 participants in the tocilizumab group and 71 in the placebo
group. All analyses were performed in STATA version 13.1. p-values
were not adjusted for multiple comparisons.
3. Results
In an assessment of missing data, of the 1220 original treatment
assignments, those with available hsTnT data at both time points
were slightly older than those with missing data (54.6 versus 52.6
years; p¼0.013), and were more likely to be white ethnicity (78.7%
versus 69.3%; p<0.001). 31.8% placebo group and 28.0% of the
tocilizumab group had hsTnT data available at both timepoints;
p¼0.165. Randomised treatment groups were broadly balanced at
baseline for key outcome variables (Table 1).
Median NT-proBNP and hsTnT concentrations were 100 pg/ml
(IQR 55, 196) and 5.73 pg/ml (IQR 3.41, 8.16) at baseline, respec-
tively. Baseline NT-proBNP and hsTnT correlated with each other
and with age; neither were associated with tender or swollen joint
count, but NT-proBNP showed modest correlations with DAS28-
ESR, IL-6, and CRP (Table 2).
The change in DAS28-ESR over 24 weeks (in both treatment
groups combined) showed no correlation with change in hsTnT
(r ¼ 0.024, p¼0.72) or with change in NT-proBNP (r ¼ 0.02,
p¼0.80). Similarly, change in CRP showed no correlation with
change in hsTnT (r ¼ 0.076, p¼0.25) but did show a modest cor-
relation with change in NT-proBNP (r ¼ 0.17, p¼0.013).
After 24 weeks, changes in DAS28-ESR and CRP in this patients
subset with available samples were consistent with data from the
main trial (Table 3). Circulating concentrations of both hsTnT and
NT-proBNP fell in both treatment groups. The extent of the decrease
in NT-proBNP was substantial, and occurred to a similar extent in
both treatment and placebo arms. The extent of the decrease in
hsTnT was less pronounced in tocilizumab treated patients than in
those in the placebo arm, such that the baseline adjusted effect was
23.3% higher in the tocilizumab arm at 24 weeks (Table 3). This
effect was not attenuated following multivariable adjustment for
allocation of escape therapy during follow-up, week 24 CRP, or
week 24 DAS28-ESR.
Data were further analysed by strata of baseline variables to test
for interaction (Fig. 1). There was no strong evidence that the effect
of tocilizumab on hsTnT concentration varied by differing levels of
baseline variables.
4. Discussion
This is one of the ﬁrst studies to investigate the effect of in-
ﬂammatory blockade on cardiac biomarkers using a randomised
placebo controlled design. In this subset of RA patients there is a
clear “trial effect” (also noted in themain trial results [17]) whereby
disease activity improved in both arms over 24 weeks, likely due to
improved adherence to conventional therapy. It is interesting that
Table 1
Distribution of baseline variables by randomised treatment group.
Variable Placebo (n ¼ 132) Tocilizumab (n ¼ 225) p-value
Age 55.0 (13.5) 54.4 (12.6) 0.640
Female sex 106 (80.3%) 189 (84.0%) 0.373
White ethnicity 101 (76.5%) 180 (80.0%) 0.302
Current smoker 23 (17.4%) 38 (16.89%) 0.897
Disease duration (years) 7 (2, 12) 8 (3, 16) 0.21
DAS28 6.59 (1.06) 6.63 (0.97) 0.683
Number of previous DMARDS 1 (0, 3) 1 (0, 3) 0.728
Baseline diabetes 14 (10.6%) 18 (8.0%) 0.445
C-reactive protein (mg/dl) 1.28 (0.63, 3.19) 1.42 (0.61, 3.03) 0.830
IL-6 (pg/ml) 21.4 (5.4, 46.6) 19.5 (8.3, 46.0) 0.929
Serum creatinine (mmol/L) 66.3 (55.3, 76.9) 62.8 (54.8, 71.6) 0.154
Tender Joint count (n/66) 27.2 (15.3) 30.0 (15.9) 0.10
Swollen joint count (n/68) 18.3 (11.5) 19.6 (12.3) 0.32
Haemoglobin (g/L) 134.7 (15.9) 133.6 (17.0) 0.51
Troponin T (pg/ml) 5.6 (3.1, 8.1) 5.9 (3.6, 8.2) 0.463
NT-proBNP (pg/ml) 92 (55, 209) 105 (54, 185) 0.798
Data are mean (standard deviation), median (inter-quartile range), or n (%).
Table 2
Baseline Spearman correlates of NT-proBNP and hsTnT (r-coefﬁcients and associated p-values).
hsTnT Age DAS28-ESR Tender joint count Swollen joint count CRP IL-6 Creatinine Haemoglobin
NT-proBNP 0.26 (p<0.001) 0.36 (p<0.001) 0.12 (p¼0.047) 0.06 (p¼0.28) 0.03 (p¼0.59) 0.27 (p<0.001) 0.22 (p<0.001) 0.01 (p¼0.89) 0.24 (p<0.001)
hsTnT 0.50 (p<0.001) 0.01 (p¼0.84) 0.06 (p¼0.31) 0.02 (p¼0.70) 0.00 (p¼0.96) 0.03 (p¼0.58) 0.28 (p<0.001) 0.10 (p¼0.09)
Table 3
Effect of tocilizumab relative to placebo on hsTnT, NT-proBNP, CRP and DAS28 in available samples.
N pairs Placebo Tocilizumab p-
valuec
Baseline adjusted relative effect of
tocilizumab
Baseline Median
(IQR)
24 week Median
(IQR)
p-
valuea
Baseline Median
(IQR)
24 week Median
(IQR)
p-
valueb
DAS28 104 placebo 208
tocilizumab
6.41 (5.82e7.27) 5.44 (4.58e6.63) <0.001 6.64 (5.96e7.36) 3.59 (2.37e4.70) <0.001 <0.001 42.6% (35.9%, 48.5%) p<0.001
CRP (mg/dl) 106 placebo 213
tocilizumab
1.15 (0.53e2.60) 0.94 (0.55e2.63) 0.31 1.50 (0.62e3.13) 0.04 (0.02e0.09) <0.001 <0.001 94.6% (92.7%, 95.9%) p<0.001
hsTnT (pg/ml) 132 placebo 225
tocilizumab
5.6 (3.1e8.1) 3.1 (1.5e5.4) <0.001 5.9 (3.6e8.2) 4.4 (1.5e7.5) <0.001 0.013 þ23.3% (þ8.0%, þ40.7%), p¼0.002
NT-proBNP
(pg/ml)
132 placebo 204
tocilizumab
92 (55e209) 77 (46e149) 0.008 105 (54, 185) 79 (42e143) <0.001 0.59 5.5% (21.4%, þ13.7%), p¼0.55
a Comparing baseline and 24 weeks in placebo group.
b Comparing baseline and 24 weeks in tocilizumab group.
c Comparing placebo and tocilizumab groups at 24 weeks.
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hsTnT and NT-proBNP in both trial arms. However, change in car-
diac biomarkers did not correlate with change in DAS28-ESR,
although NT proBNP change did correlate modestly with CRP
change. Reductions in cardiac biomarkers in both trial arms may be
consistent with suggestions that optimally treating disease activity
following enrolment into the trial (whatever therapeutic approach
is used) will reduce CVD risk [12].
The baseline NT-proBNP levels in these RA patients (median
100 pg/ml) were higher than onemight see in a general population;
indeed, median NT-proBNP in the ASCOT trial of patients with
hypertension and other CVD risk factors was 89 pg/ml [18]. The
extent of the reduction in NT-proBNP in both trial arms is fairly
substantial. In contrast, the baseline levels of hsTnT were near the
limit of detection of the high sensitivity assay, and consequently the
absolute reductions in hsTnT are small. One may speculate that the
smaller decrease in hsTnT observed in tocilizumab treated patients
could be due to a number of mechanisms including release of
troponin T from non-cardiac origins; indeed, damaged or regen-
erating skeletal muscle may express troponin T [19e21]. RA pa-
tients who experience improved quality of life and lower diseaseactivity through tocilizumab allocation might expect to increase
muscle mass through increased subsequent physical activity.
In common with data from other studies, the TOWARD trial
reported increased total cholesterol levels of around 0.8 mmol/L in
those taking tocilizumab [17]. This rise of cholesterol levels while
on tocilizumab (which is also common to TNFa blockade targeted
biologics [22]) may also provide a potential explanation for the
lesser decrease in hsTnT in the tocilizumab arm although the time
frame for this change to have biological consequences is short. Of
interest, biomarker changes in other pathways appear to be more
favourable [23]. Alternatively, type I errormay explain our observed
differences between arms. Also of importance, we observe de-
creases in hsTnT in tocilizumab treated patients, despite back-
ground rises in cholesterol levels, providing short-term reassurance
of tocilizumab being a safe treatment option from a cardiovascular
perspective. Evidence that IL-6 blockade is unlikely to cause short-
term increases in NT-proBNP, which might be a signal for heart
failure risk, in these patients is also reassuring. Endpoint driven
trials speciﬁcally investigating the inﬂammatory hypothesis of CVD
in secondary prevention patients are underway [24].
One very recent randomised controlled trial of 117 patients
Fig. 1. Relative effect of tocilizumab on hsTnT and NT-proBNP stratiﬁed by key baseline variables with p-values for test for interaction.
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levels during percutaneous coronary intervention; the median AUC
for hsTnT during hospitalization over 3 days was 50% higher in the
placebo group compared with the tocilizumab group (234 vs.
159 pg/ml, P ¼ 0.007) [25]. The setting of that study is clearly very
different from the present one, as it investigated the effect of
tocilizumab to reduce inﬂammation-mediated myocardial injury
during a speciﬁc intervention. Although the present study provided
broadly null results comparing arms, it is based on a larger number
of less acutely ill patients over a greater exposure period.
Strengths of the present study include the placebo controlled,
randomised, blinded design which offers greater ability to make
causal inferences than observational studies. The improvements in
cardiac biomarkers that we observe in the placebo arm serve to
underline the importance of a control arm. Weaknesses include the
availability of samples limited to a subgroup of patients, although
this appears to have had little impact on randomised balance. The
short term follow-upmakes it impossible to speculate as to the long
term effect of IL-6 receptor blockade. The reductions in NT-proBNP
and hsTnT we observe in both arms of the study over 24 weeks
argue against the study being insufﬁciently powered, having
insufﬁcient follow-up, or measurements of hsTnT being too close to
the assay limit of detection to observe relevant changes in cardiac
biomarkers. Further work, including investigating troponin I levels,
as well as upstream markers of CVD risk including endothelial and
prothrombotic markers [23,26], in tocilizumab treated patients is
warranted althoughwe could not undertake suchwork in TOWARD
due to limited sample volumes. The main TOWARD trial reported
vascular disorders and cardiac disorders as serious adverse events
[17]. Vascular disorders occurred in 6.7% of the tocilizumab treated
group and 5.1% of the placebo group (p¼0.25), and cardiac disorders
in 0.4% and 0.2% (p¼0.99) respectively. Given the low event rate and
small samples size we could not meaningfully investigate hard
endpoints in the present smaller subcohort.
In conclusion, although patients treated with tocilizumab (on
top of DMARDS) demonstrated substantial reductions in hsTnT andNT-proBNP, concentrations of hsTnT did not decrease to the same
extent as observed in those treated given placebo. These data offer
no direct support to the inﬂammatory hypothesis of CVD, although
they also do not rule out a causal role of inﬂammation in CVD. The
data are also perhaps consistent with a general cardiovascular
beneﬁt of improved RA treatment, regardless of the drug used.
Larger and longer term randomised controlled anti-inﬂammatory
studies are needed to expand on our ﬁndings.
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